{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:05:10Z","timestamp":1791925510001,"version":"4.3.4"},"reference-count":103,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T00:00:00Z","timestamp":1679788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Association for Research and Cure of Factor V deficiency (ASDEFAV)","award":["ASDEFAV\/2021-23"],"award-info":[{"award-number":["ASDEFAV\/2021-23"]}]},{"name":"Association for Research and Cure of Factor V deficiency (ASDEFAV)","award":["CT63\/19-CT64\/19"],"award-info":[{"award-number":["CT63\/19-CT64\/19"]}]},{"name":"Complutense University of Madrid and Banco Santander","award":["ASDEFAV\/2021-23"],"award-info":[{"award-number":["ASDEFAV\/2021-23"]}]},{"name":"Complutense University of Madrid and Banco Santander","award":["CT63\/19-CT64\/19"],"award-info":[{"award-number":["CT63\/19-CT64\/19"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Proteostasis, i.e., the homeostasis of proteins, responsible for ensuring protein turnover, is regulated by proteases, which also participate in the etiopathogenesis of multiple conditions. The magic of proteases is such that, in blood coagulation, one same molecule, such as coagulation factor V, for example, can perform both a procoagulant and an anticoagulant function as a result of the activity of proteases. However, this magic has an insidious side to it, as it may also prevent the completion of the clinical value chain of factor V deficiency. This value chain encompasses the discovery of knowledge, the transfer of this knowledge, and its translation to clinical practice. In the case of rare and ultra-rare diseases like factor V deficiency, this value chain has not been completed as the knowledge acquisition phase has dragged out over time, holding up the transfer of knowledge to clinical practice. The reason for this is related to the small number of patients afflicted with these conditions. As a result, new indications must be found to make the therapies cost-effective. In the case of factor V, significant research efforts have been directed at developing a recombinant factor V capable of resisting the action of the proteases capable of inactivating this factor. This is where bioethics and health equity considerations come into the equation.<\/jats:p>","DOI":"10.3390\/ijms24076243","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T04:05:40Z","timestamp":1679889940000},"page":"6243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9491-5572","authenticated-orcid":false,"given":"Juan A.","family":"De Pablo-Moreno","sequence":"first","affiliation":[{"name":"Department of Genetics, Physiology and Microbiology, School of Biological Sciences, Complutense University, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-2045","authenticated-orcid":false,"given":"Andrea","family":"Miguel-Batuecas","sequence":"additional","affiliation":[{"name":"Department of Genetics, Physiology and Microbiology, School of Biological Sciences, Complutense University, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"de Sancha","sequence":"additional","affiliation":[{"name":"Department of Genetics, Physiology and Microbiology, School of Biological Sciences, Complutense University, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Liras","sequence":"additional","affiliation":[{"name":"Department of Genetics, Physiology and Microbiology, School of Biological Sciences, Complutense University, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-biochem-060713-035352","article-title":"Activity-based profiling of proteases","volume":"83","author":"Sanman","year":"2014","journal-title":"Annu. Rev. Biochem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijbiomac.2019.01.081","article-title":"A systematic reconsideration on proteases","volume":"128","author":"Gurumallesh","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kolak, M., Gorecka, J., Radon-Pokracka, M., Piasecki, M., Cierniak, A., Micek, A., Horbaczewska, A., Jaworowski, A., and Huras, H. (2023). ICTP concentration in cervical-vaginal fluid as a potential marker of membrane collagen degradation before labor. Ginekol. Pol.","DOI":"10.5603\/GP.a2023.0018"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Elsworth, B., Keroack, C., Rezvani, Y., Paul, A., Barazorda, K., Tennessen, J., Sack, S., Moreira, C., Gubbels, M.J., and Meyers, M. (2023). Babesia divergens egress from host cells is orchestrated by essential and druggable kinases and proteases. Res. Sq.","DOI":"10.21203\/rs.3.rs-2553721\/v1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1351\/pac199264010143","article-title":"Glossary for chemists of terms used in biotechnology (IUPAC Recommendations 1992)","volume":"64","author":"Nagel","year":"1992","journal-title":"Pure Appl. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"D343","DOI":"10.1093\/nar\/gkr987","article-title":"MEROPS: The database of proteolytic enzymes, their substrates and inhibitors","volume":"40","author":"Rawlings","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"D624","DOI":"10.1093\/nar\/gkx1134","article-title":"The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database","volume":"46","author":"Rawlings","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/acs.analchem.9b05288","article-title":"Exopeptidase Assisted N- and C-Terminal Proteome Sequencing","volume":"92","author":"Helbig","year":"2020","journal-title":"Anal. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"112610","DOI":"10.1016\/j.foodres.2023.112610","article-title":"Discovery of specific antioxidant peptide from Chinese Dahe black pig and hybrid pig dry-cured hams based on peptidomics strategy","volume":"166","author":"Wei","year":"2023","journal-title":"Food Res. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1083\/jcb.201709072","article-title":"Pathways of cellular proteostasis in aging and disease","volume":"217","author":"Klaips","year":"2018","journal-title":"J. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","article-title":"The proteostasis network and its decline in ageing","volume":"20","author":"Hipp","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ratnikov, B.I., Cieplak, P., Remacle, A.G., Nguyen, E., and Smith, J.W. (2021). Quantitative profiling of protease specificity. PLoS Comput. Biol., 17.","DOI":"10.1371\/journal.pcbi.1008101"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129238","DOI":"10.1016\/j.bmcl.2023.129238","article-title":"Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors","volume":"86","author":"Guo","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1074\/jbc.TM118.004156","article-title":"Proteases: History, discovery, and roles in health and disease","volume":"294","author":"Bond","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"828157","DOI":"10.3389\/fnetp.2022.828157","article-title":"A Personalized Spring Network Representation of Emphysematous Lungs From CT Images","volume":"2","author":"Yuan","year":"2022","journal-title":"Front. Netw. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1026810","DOI":"10.3389\/fmolb.2023.1026810","article-title":"Proteolysis of CD44 at the cell surface controls a downstream protease network","volume":"10","author":"Li","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4997\/JRCPE.2014.110","article-title":"Coagulation","volume":"44","author":"Chee","year":"2014","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/labmed\/lmx050","article-title":"Coagulation Testing in the Core Laboratory","volume":"48","author":"Winter","year":"2017","journal-title":"Lab. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J. Anaesth."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/a-1938-1984","article-title":"Global Coagulation Testing in Acute Care Medicine: Back to Bedside?","volume":"42","author":"Caspers","year":"2022","journal-title":"Hamostaseologie"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"De Souza, D.A., Salu, B.R., Nogueira, R.S., de Carvalho Neto, J.C.S., Maffei, F.H.A., and Oliva, M.L.V. (2023). Peptides Derived from a Plant Protease Inhibitor of the Coagulation Contact System Decrease Arterial Thrombus Formation in a Murine Model, without Impairing Hemostatic Parameters. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051810"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3389\/fphys.2018.01623","article-title":"Indoxyl Sulfate Promotes Arterial Thrombosis in Rat Model via Increased Levels of Complex TF\/VII, PAI-1, Platelet Activation as Well as Decreased Contents of SIRT1 and SIRT3","volume":"9","author":"Karbowska","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1038\/s41598-023-30884-6","article-title":"An agent-based approach for modelling and simulation of glycoprotein VI receptor diffusion, localisation and dimerisation in platelet lipid rafts","volume":"13","author":"Tantiwong","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/BF03022247","article-title":"From normal to pathological hemostasis","volume":"53","author":"Lasne","year":"2006","journal-title":"Can. J. Anesth. Can. Anesth."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"NaveenKumar, S.K., Hemshekhar, M., Sharathbabu, B.N., Kemparaju, K., Mugesh, G., and Girish, K.S. (2023). Platelet activation and ferroptosis mediated NETosis drives heme induced pulmonary thrombosis. Biochim. Biophys. Acta Mol. Basis Dis., 166688.","DOI":"10.1016\/j.bbadis.2023.166688"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kaufmanova, J., Stikarova, J., Hlavackova, A., Chrastinova, L., Maly, M., Suttnar, J., and Dyr, J.E. (2021). Fibrin Clot Formation under Oxidative Stress Conditions. Antioxidants, 10.","DOI":"10.3390\/antiox10060923"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1008410","DOI":"10.3389\/fcvm.2022.1008410","article-title":"Intrinsic coagulation pathway-mediated thrombin generation in mouse whole blood","volume":"9","author":"Konrath","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41536-022-00230-x","article-title":"Therapeutic use of \u03b12-antiplasmin as an antifibrinolytic and hemostatic agent in surgery and regenerative medicine","volume":"7","author":"Liu","year":"2022","journal-title":"N.P.J. Regen. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1152\/physrev.1929.9.3.399","article-title":"Organization for physiological homeostasis","volume":"9","author":"Cannon","year":"1929","journal-title":"Physiol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cannon, W.B. (1932). The Wisdom of the Body, The Norton Library.","DOI":"10.1097\/00000441-193212000-00028"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"113712","DOI":"10.1016\/j.physbeh.2022.113712","article-title":"A critique on the theory of homeostasis","volume":"247","year":"2022","journal-title":"Physiol. Behav."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2183472","DOI":"10.1080\/14767058.2023.2183472","article-title":"Evaluation of maternal serum SERPINC1, E-selectin, P-selectin, RBP4 and PP13 levels in pregnancies complicated with preeclampsia","volume":"36","author":"Palalioglu","year":"2023","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bpj.2022.11.023","article-title":"Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI","volume":"122","author":"Miyazawa","year":"2023","journal-title":"Biophys. J."},{"key":"ref_34","first-page":"e34012","article-title":"Hereditary Protein S Deficiency and Activated Protein C Resistance Manifesting With Recurrent Thrombosis and Stroke","volume":"15","author":"Finsterer","year":"2023","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"105413","DOI":"10.1016\/j.meegid.2023.105413","article-title":"Structural and genomic analysis of single nucleotide polymorphisms in human host factor endothelial protein C receptor (EPCR) reveals complex interplay with malaria parasites","volume":"110","author":"Gill","year":"2023","journal-title":"Infect. Genet. Evol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tem.2022.02.003","article-title":"Proteostasis and resilience: On the interphase between individual\u2019s and intracellular stress","volume":"33","author":"Hetz","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Al-Koussa, H., AlZaim, I., and El-Sabban, M.E. (2022). Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164932"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood.2020008417","article-title":"Factor VIIa induces extracellular vesicles from the endothelium: A potential mechanism for its hemostatic effect","volume":"137","author":"Das","year":"2021","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Georgatzakou, H.T., Fortis, S.P., Papageorgiou, E.G., Antonelou, M.H., and Kriebardis, A.G. (2022). Blood Cell-Derived Microvesicles in Hematological Diseases and beyond. Biomolecules, 12.","DOI":"10.3390\/biom12060803"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Soares, J.P.M., Gon\u00e7alves, D.A., de Sousa, R.X., Mouro, M.G., Higa, E.M.S., Sperandio, L.P., Vitoriano, C.M., Rosa, E.B.S., Santos, F.O.D., and de Queiroz, G.N. (2022). Disruption of Redox Homeostasis by Alterations in Nitric Oxide Synthase Activity and Tetrahydrobiopterin along with Melanoma Progression. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23115979"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.12998\/wjcc.v10.i1.236","article-title":"Acquired coagulation dysfunction resulting from vitamin K-dependent coagulation factor deficiency associated with rheumatoid arthritis: A case report","volume":"10","author":"Huang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.24222","article-title":"Factor V Leiden","volume":"91","author":"Khor","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database","volume":"28","author":"Lambert","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: Therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drudis.2017.11.002","article-title":"Rare genetic diseases: Update on diagnosis, treatment and online resources","volume":"23","author":"Pogue","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1182\/asheducation-2003.1.559","article-title":"Congenital bleeding disorders","volume":"2003","author":"Rick","year":"2003","journal-title":"Hematol. Am. Soc. Hematol. Educ. Programm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cppeds.2004.12.001","article-title":"Congenital bleeding disorders","volume":"35","author":"Brown","year":"2005","journal-title":"Curr. Probl. Pediatr. Adolesc. Health Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.hoc.2017.08.011","article-title":"Evaluation and Management of Congenital Bleeding Disorders","volume":"31","author":"Bhat","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.hoc.2021.07.010","article-title":"Rare Coagulation Factor Deficiencies (Factors VII, X, V, and II)","volume":"35","author":"Batsuli","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/s-0039-1687906","article-title":"A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency","volume":"45","author":"Tabibian","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Dorgalaleh, A. (2018). Congenital Bleeding Disorders, Springer.","DOI":"10.1007\/978-3-319-76723-9"},{"key":"ref_52","unstructured":"(2023, February 24). The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff (HGMD). Available online: http:\/\/www.hgmd.cf.ac.uk\/ac\/index.php."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1021\/bi00130a007","article-title":"Structure of the gene for human coagulation factor V","volume":"31","author":"Cripe","year":"1992","journal-title":"Biochemistry"},{"key":"ref_54","first-page":"19","article-title":"Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation","volume":"2","author":"Bos","year":"2010","journal-title":"J. Coagul. Disord."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/MPH.0000000000002261","article-title":"Clinical Phenotype and Genetic Analysis of Twins With Congenital Coagulation Factor V Deficiency","volume":"44","author":"Wei","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000363598","article-title":"Congenital factor V deficiency: Comparison of the severity of clinical presentations among patients with rare bleeding disorders","volume":"133","author":"Naderi","year":"2015","journal-title":"Acta Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.transci.2018.10.009","article-title":"Management of rare coagulation disorders in 2018","volume":"57","author":"Jain","year":"2018","journal-title":"Transfus. Apher. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.14531","article-title":"Therapeutic and technological advancements in haemophilia care: Quantum leaps forward","volume":"28","author":"Lewandowska","year":"2022","journal-title":"Haemophilia"},{"key":"ref_59","unstructured":"U.S. National Library of Medicine (2023, February 24). A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors (explorer\u21225). ClinicalTrials.gov Identifier: NCT03196297, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03196297?term=Concizumab&draw=2&rank=5."},{"key":"ref_60","unstructured":"U.S. National Library of Medicine (2023, February 24). A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device. ClinicalTrials.gov Identifier: NCT04832139, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04832139?term=Marstacimab&draw=2&rank=1."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/jth.15052","article-title":"Anticoagulant and signaling functions of antithrombin","volume":"18","author":"Rezaie","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_62","unstructured":"U.S. National Library of Medicine (2023, February 24). Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX (ATLAS-OLE). ClinicalTrials.gov Identifier: NCT03754790, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03754790?term=Fitusiran&draw=2&rank=3."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8793","DOI":"10.1038\/s41598-018-27067-z","article-title":"Identification of serpins specific for activated protein C using a lysate-based screening assay","volume":"8","author":"Polderdijk","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_64","unstructured":"U.S. National Library of Medicine (2023, February 24). The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (Haemophilia A and B). ClinicalTrials.gov Identifier: NCT04073498, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04073498?term=SerpinPC&draw=2&rank=1."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2020.05.026","article-title":"Protein C deficiency presenting as an acute infero-posterior ST elevation myocardial infarction in a young man; A case report and focused literature review","volume":"192","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_66","unstructured":"Gupta, A., Tun, A.M., Gupta, K., and Tuma, F. (2022). Protein S Deficiency, StatPearls Publishing."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Trivedi, R., and Nagarajaram, H.A. (2022). Intrinsically Disordered Proteins: An Overview. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214050"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"10466","DOI":"10.1039\/c2cp41196b","article-title":"Rate constants and mechanisms of intrinsically disordered proteins binding to structured targets","volume":"14","author":"Zhou","year":"2012","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008951","article-title":"Plasminogen: An enigmatic zymogen","volume":"137","author":"Keragala","year":"2021","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1538-7836.2009.03365.x","article-title":"Slow thrombin is zymogen-like","volume":"7","author":"Huntington","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100062","DOI":"10.1016\/j.rpth.2023.100062","article-title":"In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype","volume":"7","author":"Verhagen","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/01.ATV.0000012665.51263.B7","article-title":"Factor V and thrombotic disease: Description of a janus-faced protein","volume":"22","author":"Nicolaes","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Shimonishi, N., Ogiwara, K., Yoshida, J., Horie, K., Nakajima, Y., Furukawa, S., Takeyama, M., and Nogami, K. (2023). Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations. Blood Adv., bloodadvances.2022008918.","DOI":"10.1182\/bloodadvances.2022008918"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1160\/TH11-06-0431","article-title":"The anticoagulant function of coagulation factor V","volume":"107","author":"Cramer","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9335","DOI":"10.1074\/jbc.M116.769570","article-title":"Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation","volume":"292","author":"Santamaria","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)02225-X","article-title":"Blood coagulation","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1365-2516.2002.00633.x","article-title":"Rare coagulation deficiencies","volume":"8","author":"Peyvandi","year":"2002","journal-title":"Haemophilia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood.2021010684","article-title":"Cryo-EM structures of human coagulation factors V and Va","volume":"137","author":"Ruben","year":"2021","journal-title":"Blood"},{"key":"ref_79","first-page":"76","article-title":"Defining the structure of membrane-bound human blood coagulation factor Va: Defining the structure of human blood coagulation factor Va","volume":"6","author":"Parmenter","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"gzaa029","DOI":"10.1093\/protein\/gzaa029","article-title":"Construction, characterization and crystal structure of a fluorescent single-chain FV chimera","volume":"34","author":"Velappan","year":"2021","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1073\/pnas.0403072101","article-title":"The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function","volume":"101","author":"Adams","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"27393","DOI":"10.1074\/jbc.M503435200","article-title":"Incorporation of Factor Va into Prothrombinase Is Required for Coordinated Cleavage of Prothrombin by Factor Xa","volume":"280","author":"Bukys","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/prot.20848","article-title":"Proposed structural models of the prothrombinase (FXa-FVa) complex","volume":"63","author":"Autin","year":"2006","journal-title":"Proteins"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1021\/bi981966e","article-title":"A Model Describing the Inactivation of Factor Va by APC: Bond Cleavage, Fragment Dissociation, and Product Inhibition","volume":"38","author":"Hockin","year":"1999","journal-title":"Biochemistry"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Sim, D.S., Shukla, M., Mallari, C.R., Fern\u00e1ndez, J.A., Xu, X., Schneider, D., Bauzon, M., Hermiston, T.W., and Mosnier, L.O. (2023). Selective Modulation of Activated Protein C Activities by a Non-Active Site Targeting Nanobody Library. Blood Adv., bloodadvances.2022008740.","DOI":"10.1182\/bloodadvances.2022008740"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2023.02.024","article-title":"Investigation of cofactor activities of endothelial microparticle-thrombomodulin with liposomal surrogate","volume":"651","author":"Gruzdys","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ijlh.12508","article-title":"Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders","volume":"38","year":"2016","journal-title":"Int. J. Lab. Hemtol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2013-10-530089","article-title":"Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden","volume":"123","author":"Nogami","year":"2014","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1055\/s-0038-1656549","article-title":"Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPI\u03b1: Difference between FV1 and FV2","volume":"118","author":"Rosing","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_90","first-page":"00095","article-title":"Natural anticoagulant discovery, the gift that keeps on giving: Finding FV-Short","volume":"S1538\u2013S7836","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2018-06-820738","article-title":"Treatment of rare factor deficiencies other than hemophilia","volume":"133","author":"Menegatti","year":"2019","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1423-0410.2009.01190.x","article-title":"Biochemical quality of the pharmaceutically licensed plasma OctaplasLG\u00ae after implementation of a novel prion protein (PrP Sc) removal technology and reduction of the solvent\/detergent (S\/D) process time","volume":"97","author":"Heger","year":"2009","journal-title":"Vox Sang."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"von Drygalski, A., Bhat, V., Gale, A.J., Burnier, L., Cramer, T.J., Griffin, J.H., and Mosnier, L.O. (2014). An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104304"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s11095-016-1895-3","article-title":"Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding","volume":"33","author":"Gale","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/bloodadvances.2021005257","article-title":"An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice","volume":"6","author":"Joseph","year":"2022","journal-title":"Blood Adv."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"104698","DOI":"10.1016\/j.isci.2022.104698","article-title":"Estimating the number of diseases\u2014The concept of rare, ultra-rare, and hyper-rare","volume":"25","author":"Smith","year":"2022","journal-title":"iScience"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMp2112233","article-title":"Combating Structural Inequities\u2014Diversity, Equity, and Inclusion in Clinical and Translational Research","volume":"386","author":"Boulware","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/d41586-018-05049-5","article-title":"When will clinical trials finally reflect diversity?","volume":"557","author":"Knepper","year":"2018","journal-title":"Nature"},{"key":"ref_99","unstructured":"Inherited Hemophilia, A. (2023, February 24). The Portal for Rare Diseases and Orphan Drugs (Orphanet). Available online: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Expert=98878&lng=EN."},{"key":"ref_100","unstructured":"(2023, February 24). Congenital Factor V Deficiency. The Portal for Rare Diseases and Orphan Drugs (Orphanet). Available online: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=GB&Expert=326."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s13023-022-02476-6","article-title":"Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases","volume":"17","author":"Douglas","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.drudis.2022.01.013","article-title":"Drug repositioning trends in rare and intractable diseases","volume":"27","author":"Sakate","year":"2022","journal-title":"Drug. Discov. Today"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cge.14113","article-title":"CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative","volume":"101","author":"Luque","year":"2022","journal-title":"Clin. Genet."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:03:20Z","timestamp":1760123000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,26]]},"references-count":103,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076243"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076243","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,26]]}}}